Aldeyra Therapeutics (NASDAQ:ALDX) announced FDA acceptance of its resubmitted market application for topical ocular reproxalap for the treatment of dry eye disease and an expansion of its option agreement with AbbVie (NYSE:ABBV).
(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.)
Why do I feel better rested when I...
